“Among patients with hormone receptor-positive, HER2-negative, early-stage breast cancer, which accounts for about 70% of cases, a major challenge is identifying those who benefit from adjuvant chemotherapy given after surgery or radiation to destroy lingering microscopic cancer cells and reduce the risk of recurrence.”

“Researchers from the Technion-Israel Institute of Technology in Haifa, together with oncologists and pathologists from leading medical centers abroad – including Dana Farber Cancer Institute in Boston, Mount Sinai Medical Center in New York, the University of Chicago Medical Center, and the Institute of Molecular Pathology and Immunology of the University of Porto in Portugal – have developed an artificial intelligence model that predicts both the risk of breast cancer recurrence and the likelihood that a patient will benefit from chemotherapy.”

“The study has just been published in The Lancet Oncology under the title “Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.””

“Shamai received his doctorate from the Technion’s Electrical Engineering Department and is a research associate at Kimmel’s lab in the Taub Faculty of Computer Science.”

“It was presented to an enthusiastic audience at the 50th European Society for Medical Oncology (ESMO) conference in Berlin last December, which focused on precision medicine, antibody-drug conjugates, and cancer survivorship.”